tbuckley/cabot-search huggingface dataset:
Gene Expression Profiling Using a Reverse Transcriptase-Multiplex Ligation Dependant Probe Amplification Assay Allows for an Accurate Classification of Peripheral T-Cell Lymphoma and Highlights Novel Subgroups within the PTCL-NOS Category
Authors: Fanny Drieux, Philippe Ruminy, Virginie Fataccioli, Vinciane Marchand, Marie Parrens, Céline Bossard, Pierre Julien Viailly, Maria Pamela Dobay, Elena Liana Veresezan, Anais Pujals, Aurélie Dupuy, Jean-Michel Picquenot, Hervé Tilly, Laurence de Leval, Fabrice Jardin, Philippe Gaulard
Journal: Blood (2016)
Ischemia and No Obstructive Coronary Artery Disease (INOCA)
Authors: C. Noel Bairey Merz, Carl J. Pepine, Mary Norine Walsh, Jerome L. Fleg, Paolo G. Camici, William M. Chilian, Janine Austin Clayton, Lawton S. Cooper, Filippo Crea, Marcelo Di Carli, Pamela S. Douglas, Zorina S. Galis, Paul Gurbel, Eileen M. Handberg, Ahmed Hasan, Joseph A. Hill, Judith S. Hochman, Erin Iturriaga, Ruth Kirby, Glenn N. Levine, Peter Libby, Joao Lima, Puja Mehta, Patrice Desvigne-Nickens, Michelle Olive, Gail D. Pearson, Arshed A. Quyyumi, Harmony Reynolds, British Robinson, George Sopko, Viviany Taqueti, Janet Wei, Nanette Wenger
Journal: Circulation (2017)

The Cardiovascular Disease in Women Committee of the American College of Cardiology, in conjunction with interested parties (from the National Heart, Lung, and Blood Institute, American Heart Association, and European Society of Cardiology), convened a working group to develop a consensus on the syndrome of myocardial ischemia with no obstructive coronary arteries. In general, these patients have elevated risk for a cardiovascular event (including acute coronary syndrome, heart failure hospitalization, stroke, and repeat cardiovascular procedures) compared with reference subjects and appear to be at higher risk for development of heart failure with preserved ejection fraction. A subgroup of these patients also has coronary microvascular dysfunction and evidence of inflammation. This document provides a summary of findings and recommendations for the development of an integrated approach for identifying and managing patients with ischemia with no obstructive coronary arteries and outlines knowledge gaps in the area. Working group members critically reviewed available literature and current practices for risk assessment and state-of-the-science techniques in multiple areas, with a focus on next steps needed to develop evidence-based therapies. This report presents highlights of this working group review and a summary of suggested research directions to advance this field in the next decade.
LACK OF TESTOSTERONE IN OBESE-INSULIN RESISTANT CONDITION AGGRAVATES CARDIOMETABOLIC DYSFUNCTION THROUGH THE IMPAIRMENT OF CARDIAC MITOCHONDRIAL FUNCTION
Authors: Nattayaporn Apaijai, Titikorn Chunchai, Siripong Palee, Thidarat Jaiwongkam, Siriporn Chattipakorn, Nipon Chattipakorn
Journal: Journal of the American College of Cardiology (2017)
The Utility of 68Ga-PSMA PET/CT in Poorly Differentiated Metastatic Prostate Cancer
Authors: Mehmet Onur Demirkol, Murat Can Kiremit, Omer Acar, Burcu Ucar, Yesim Saglican
Journal: Clinical Nuclear Medicine (2017)

We aimed to emphasize how useful PSMA PET/CT findings can be while trying to restage prostate cancer after radical prostatectomy in the presence of low prostate-specific antigen values. A 64-year-old man with pT3b N1 M0 Gleason 7 adenocarcinoma of the prostate presented 5 years postoperatively with a palpable axillary mass, whereas his prostate-specific antigen was 0.08 ng/mL. Conventional imaging studies and histopathologic findings of the axillary mass biopsy revealed inconclusive results. Ga-PSMA PET/CT demonstrated PSMA-positive metastatic lesions, the largest one being located in the right axilla. This finding confirmed metastatic poorly differentiated prostate cancer, and androgen deprivation therapy was initiated.
Prise en charge endoscopique des fistules gastriques après sleeve gastrectomy par prothèses double queue de cochon: Technique BARTOLI
Authors: C Deschepper, L Rebibo, JP Le Mouel, H Thiebault, A Wacrenier, F Brazier, M Fumery, R Delcenserie, C Cosse, A Dhahri, JL Dupas, JM Regimbeau, E Nguyen-Khac, H Sami
Journal: Endoscopy (2017)

La fistule gastrique (FG) après sleeve gastrectomy (SG) est la principale complication postopératoire précoce, présente dans 2.5% des cas. Aucun consensus n'existe sur les modalités de sa prise en charge. L'objectif de cette étude était d'évaluer l'efficacité du drainage endoscopique interne de ces fistules par mise en place de prothèses double queue de cochon (PDQC).
Death during study treatment: An evaluation of events in 31 German clinical trials.
Authors: Jenny Furlanetto, Gunter Von Minckwitz, Bianca Lederer, Volker Möbus, Hans-Joachim Lueck, Claus Hanusch, Christoph Thomssen, Michael Untch, Sibylle Loibl
Journal: Journal of Clinical Oncology (2015)

1036 Background: Information on deaths occurring during oncological clinical trials has never been systematically assessed to describe patient, tumor, and treatment characteristics. Methods: Information on patients´ deaths during German Breast Group (GBG) led breast cancer (BC) trials was prospectively captured. In addition to the trial databases, data were derived from death narratives that included autopsy results if performed. All deaths were evaluated for possible causes, underlying conditions, treatment relatedness, time point and rate of autopsies. Results: From 12/1996 to 12/2014 23,570 patients were treated within 31 trials. Of those 75 (0.3%) died on therapy within 14 trials. 29/12,956 patients died in neoadjuvant (0.2%), 35/9,851 in adjuvant (0.3%) and 11/763 in metastatic studies (1.4%). Median age was 64 yrs (range 35-84), 63.5% of patients had an abnormal BMI (25.7% underweight, 32.4% overweight, 5.4% obese); 60% had 1-3 and 13.3% ≥ 4 comorbidities; 56% had 1-2 cardiovascular risk factors (CRFs); 45.3% took ≥ 3 drugs; 80% had an ECOG 0. Over 50% of patients had a stage III tumor at baseline with a luminal B-like BC subtype (HR+/Her2-/G3). More patients with advanced disease had a high BMI (p = 0.024), ≥ 3 comorbidities (p = 0.013) and CRFs (p = 0.001) compared to early stage patients. Main causes of death were infections (34.7%; febrile neutropenia 4%), cardiac (14.7%) and respiratory disorders (12%). 13% of patients (4 in metastatic BC, 6 in early BC) had a disease progression. 42.5% of patients received taxane (T)-based chemotherapy (CT) and the event mostly occurred in the first 4 cycles. Relatedness to chemotherapy was declared in 55% of patients, mainly when a T-based CT was given (51.2% for T-based CT, 14.6% for anthracycline (A)-based CT, 22% for A-T-based CT, 12.2% for other regimens (capecitabine, bevacizumab, lapatinib, CMF, celecoxib), none for hormone therapy); p = 0.001). An autopsy was performed in 13% of patients. Conclusions: Death during study treatment was mainly related to infections, and patients with advanced disease, high BMI, underlying comorbidities and CRFs. If considered for study participation these patients need careful monitoring due to their higher risk for death on study.
Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Acute Leukemias: A Subgroup Analysis from the Defibrotide Expanded-Access Program
Authors: Paul G. Richardson, Angela R. Smith, Brandon M. Triplett, Nancy A. Kernan, Stephan A. Grupp, Joseph H. Antin, Leslie Lehmann, Wei Liang, Robin Hume, William Tappe, Robert J. Soiffer
Journal: Blood (2016)
A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001
Authors: Vincent Ribrag, Julio C. Chavez, Jason B Kaplan, Umberto Vitolo, Jason C. Chandler, Armando Santoro, Paolo Corradini, Philippe Cassier, Ian W. Flinn, Ranjana Advani, Randeep Sangha, Iris Isufi, Vaishalee P. Kenkre, Patrick R. Hagner, Torsten Trowe, Anita K. Gandhi, Xiaoling Wu, Kristen Hege, Michael Pourdehnad, John Kuruvilla
Journal: Blood (2016)
Differential effects of metformin on breast cancer proliferation according to insulin resistance and tumor subtype in a presurgical trial.
Authors: Andrea De Censi, Matteo Lazzeroni, Valentina Aristarco, Matteo Puntoni, Sara Gandini, Aliana Guerrieri-Gonzaga, Harriet Ann Johansson, Massimiliano Cazzaniga, Giancarlo Pruneri, Davide Serrano, Matthias Schwab, Serena Mora, Debora Macis, Fabio Bassi, Alberto Luini, Bernardo Bonanni, Michael N. Pollak
Journal: Journal of Clinical Oncology (2014)

599 Background: Treatment of diabetics with metformin decreases breast cancer risk in observational studies, but it is unclear if this drug has clinical antineoplastic activity. In a recent pre-surgical trial (Bonanni et al JCO 2012), we found a heterogeneous effect of metformin on Ki-67 depending upon insulin resistance (HOMA index). Here we determined the associations of additional biomarkers of insulin resistance, tumor subtype, and serum drug concentration with Ki-67 response to metformin. Methods: 200 non-diabetics were randomly allocated to either metformin (850 mg/bid) or placebo for 4 weeks prior to breast cancer surgery. Response was assessed by comparing baseline biopsy (Ki-67 and tumor subtype) and serum markers (HOMA, C-peptide, IGF-I, IGFBP-1, IGFBP-3, hsC-reactive protein, adiponectin) with the same measurements at surgery. For patients with a blood sample taken <24 hours from last drug intake, metformin level was measured. Results: Compared with placebo, metformin decreased Ki-67 in women with HOMA>2.8, bottom IGFBP-1 quintile, top IGFBP-3 quartile, CRP>2.5 mg/L, and HER2+ve tumors (table). When HOMA was>2.8, serum drug levels were positively correlated with Ki-67 decrease, whereas no trend was noted for HOMA<2.8 (p interaction=.07). Conclusions: At antidiabetic doses, the effect of metformin on tumor Ki-67 of nondiabetic breast cancer patients is modest and varies with host and tumor characteristics. These findings are relevant to clinical trials of metformin in breast cancer prevention and treatment. Clinical trial information: ISRCTN16493703.Median (IQR) Ki-67 changes (post-pre treatment) by arm and biomarker threshold. Risk biomarker threshold N Placebo Metformin P interaction HOMA index >2.8 53 0 (-2.0; 5.0) 0 (-5.0; 2.5) 0.03 HOMA index ≤2.8 142 0 (-2.0; 4.0) +1 (-2.0; 7.0) hsCRP>1.81mg/L (3rdtertile) 65 +2.5 (0;7) 0 (-3; 4) 0.02 hsCRP≤1.81 mg/L 131 0 (-3;5) +0.5 (-2; 8) IGFBP-3>4.6ug/mL (4thquartile) 50 0 (-5.0; 7.0) 0 (-4.0; 2.0) 0.04 IGFBP-3≤4.6ug/mL 146 0 (-1.5; 4.0) +1 (-3.0; 7.0) IGFBP-1<2 ng/mL (1thquintile) 40 +1 (-5.0; 14.0) 0 (-4.0; 5.0) 0.02 IGFBP-1≥2 ng/mL 156 0 (-2.0; 4.0) +0.5 (-3.0; 7.0) HER2+ve 22 +3.5 (0; 14.0) +0.5 (-4.0; 8.0) 0.07 HER2-ve 174 0 (-3.0; 4.0) 0 (-3.0; 7.0)
CHRONIC KIDNEY DISEASE IN ASIAN PATIENTS WITH HEART FAILURE
Authors: Jasper Tromp, Katherine T.H. Teng, Wan Ting Tay, Inder Anand, Shu Zhang, Wataru Shimizu, Calambur Narasimhan, S.W. Park, Cheuk-Man Yu, Tachapong Ngarmukos, Razali Omar, Eugene B. Reyes, Chung-Lieh Hung, Lieng Ling, Jonathan Yap, Michael Ross MacDonald, Mark Richards, Carolyn Lam
Journal: Journal of the American College of Cardiology (2017)
Prognostic significance of early dynamics of peripheral blood counts in patients with AML/MDS undergoing induction chemotherapy.
Authors: Nicholas James Short, Christopher Brent Benton, Graciela M. Nogueras-Gonzalez, Jeffrey Hokanson, Lisa Gu, Farhad Ravandi, Guillermo Garcia-Manero, Mark Brandt, Sherry Pierce, Marina Konopleva, Jorge E. Cortes, Hagop M. Kantarjian, Alfonso Quintas-Cardama, Michael Andreeff
Journal: Journal of Clinical Oncology (2015)

e18045 Background: The prognostic significance of early dynamics of peripheral blood blast cell (PBBC) clearance during induction chemotherapy for AML/MDS has not been fully established when compared to other prognostic factors and for various induction regimens. Methods: Time to PBBC clearance was examined in 259 patients with AML or high-risk MDS who had detectable PBBCs at protocol baseline. All patients received idarubicin and ara-C (IA) based induction with idarubicin 12 mg/m2 x 3d and ara-C 1.5 g/m2 x 3-4d. In total, 135 (52%) patients received IA alone, 43 (17%) received IA + sorafenib (400mg PO bid x 7d concomitant with IA) and 81 (31%) received IA + vorinostat (500mg PO tid x 3d prior to IA). Additional modeling based on dynamics of daily PBBC and WBC counts was also performed. Results: Median time to PBBC clearance was 4 days (range 0-72). Median time to PBBC clearance was significantly longer in IA + vorinostat (5 days) compared to either IA or IA + sorafenib (both 3 days) (P < 0.0001). PBBC clearance ≤ 5 days post-induction occurred in 85% of patients treated with IA, 93% with IA + sorafenib and 53% with IA + vorinostat (P < 0.001 for IA + vorinostat vs. others). On univariate analysis, PBBC clearance ≤ 5 days vs. > 5 days was associated with a higher CR rate (66% vs. 38%, P < 0.001), longer median RFS (9.1 vs. 5.0 months, P = 0.001) and longer OS (14.5 vs. 7.4 months, P < 0.001). On multivariate analysis that included regimen, age, prior therapy, cytogenetics, absolute PBBC count, BM blast %, CD34+ % and NPM1 and FLT3 status, PBBC clearance ≤ 5 days vs. > 5 days was not an independent predictor of RFS or OS, although there was a trend toward higher CR rates with PBBC clearance ≤ 5 days (OR 3.1 [0.8-11.9], P = 0.091). Mathematical modeling showed that patients with day 1 / day 0 PBBC ratio ≥ 0.61 and concomitant day 1 / day 0 WBC ratio ≥ 0.43 had significantly shorter RFS (P = 0.01 and 0.07 for training and validation cohorts, respectively). Conclusions: PBBC clearance ≤ 5 days was associated with significantly higher CR rates and longer RFS and OS in patients with AML/MDS undergoing IA-based induction chemotherapy. Specialized modeling showed that dynamics of daily PBBC and WBC counts facilitate early prediction of relapse.
PULMONARY VENOUS WAVEFORMS PREDICT VENTRICULAR REMODELING AFTER PERCUTANEOUS MITRAL VALVE REPAIR
Authors: Frank Corrigan, Aneel Maini, Ankit Parikh, Ioannis Parastatidis, Patricia Keegan, Sharon Howell, Vinod Thourani, Stephen Clements, Vasilis Babaliaros, Stamatios Lerakis
Journal: Journal of the American College of Cardiology (2017)
A BUNDLED INTERVENTION INCLUDING EARLY CONSULTATION WITH A CARDIOLOGIST IN THE EMERGENCY DEPARTMENT TO REDUCE RE-HOSPITALIZATIONS AND HEALTHCARE COST FOR HIGH-RISK URBAN PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE
Authors: Corey Tabit, Mitchell Coplan, Kirk Spencer, Rupa Sanghani, James Liao
Journal: Journal of the American College of Cardiology (2017)
Endogenous steroid hormone concentrations and risk of breast cancer: Does the association vary by a woman’s predicted breast cancer risk?
Authors: A. Heather Eliassen, Stacey A. Missmer, Shelley S. Tworoger
Journal: Cancer Research (2005)

3212  Endogenous hormones are associated with an increased risk of breast cancer in postmenopausal women, but whether the association varies by a woman’s predicted risk of breast cancer has not been investigated in detail. To assess this question, we evaluated the associations of plasma levels of estradiol and testosterone with subsequent risk of breast cancer in a prospective, nested case-control study within the Nurses’ Health Study. Blood samples were collected in 1989-90; among 11,169 postmenopausal women not using postmenopausal hormones, 417 cases of breast cancer were reported through June 2000. Two controls were matched per case on age, fasting status, and month and time of day of blood draw (n=816). Women were classified both by first-degree family history of breast cancer and predicted risk of breast cancer. We used a modified Gail model to calculate predicted risk of invasive breast cancer in the 5 years following blood collection, based on age, ages at menarche and first live birth, number of affected first-degree relatives, and here, history of benign breast disease. We also stratified by risk scores from the Rosner risk prediction model. Multivariate relative risks (RR) and 95% confidence intervals (CI) were calculated by unconditional logistic regression, adjusting for matching factors and breast cancer risk factors. Among women with a family history (104 cases, 143 controls), estradiol was associated with an increased risk of breast cancer (top vs. bottom fourth, RR=3.5, 95% CI (1.5-7.9), p-trend=0.002), while testosterone was not associated with risk, (comparable RR=1.0, 95% CI (0.4-2.3), p-trend=0.87). Among women with a modified Gail predicted risk of breast cancer ≥1.66% (252 cases, 460 controls), both hormones were associated with an increased risk of breast cancer (top vs. bottom fourth, RR=2.2, 95% CI (1.4-3.4), p-trend
IDH 1 /2 status and low grade gliomas (LGG): Correlation with outcome upfront Pignatti criteria and molecular profile in a retrospective analysis of a single-centre cohort from Spain.
Authors: Olatz Etxaniz, Cristina Carrato, Itziar de Aguirre, Cristina Queralt, Ana Munoz, Jose Luis Ramirez, Rafael Rosell, Salvador Villà, Rocio Diaz, Anna Estival, Pilar Teixidor, Alberto Indacochea, Sara Ahlal, Laia VilÃ Martinez, Carmen Balana
Journal: Journal of Clinical Oncology (2015)

2046 Background: Current therapy of LGG is based on clinical, radiologic and histologic ( Pignatti prognostic classification ) features .In the last years genomic profile of LGG has been investigated showing a new tool to guide therapy . Methods: IDH analysis was performed by IDH1 and IDH2 genes sequencing in a series of 58 LGGs diagnosed from 1991 to 2012 and correlated with histology , Pignatti classification , molecular profile ( p53 expression , 1p19q deletion status and MGMT promoter methylation ) and outcome. Results: 56.9% of the pts were male and mean age was 45 years . Histological distribution was 39.7% , 22.4% and 37.9% for Astrocytoma (A), Oligodendroglioma (OD) and Oligoastrocytoma (OA) , respectively . Surgical resection was total in 41.4% , subtotal in 19% and only biopsy in 39.7% of the cases . Pts were classified by Pignatti criteria. Inmediate postsurgery therapy was administered performed in 41.4% of pts. IDH alterations were found in 61.9% ( 26/42) , 1p19q codeletion in 46.3% ( 25/54), overexpression of p53 in 17.3% (9/52) and MGMT methylation in 40.4% (19/47) of the cases .Median TTP was 61.6 months ( 95% CI 25.3-97.9) and median OS was 109.7 months ( 95%CI 73.0- 146.5). In univariate analysis ,1p19q codeletion ( p = 0.045) and IDH mutation (p < 0.001 ) were associated with better TTP . Median OS was correlated with Pignatti classification ( p = 0.024 ) and IDH mutation (p < 0.001) . A trend to a better OS was observed with 1p19q codeletion ( p = 0.052) and MGMT methylation( p = 0.068 ). In multivariate analysis, IDH mutation was the only independent prognostic factor after adjustment for histology, molecular profile and Pignatti criteria in terms of OS ( HR = 0.120, 95%CI 0.031-0.459, p = 0.002 ) and TTP ( HR 0.237,95%CI 0.072-0.779, p = 0.018 ). Conclusions: Our findings confirmed the favorable prognostic independent value of IDH mutation in LGG over other criteria.
Circulating tumor cells (CTCs) as a surrogate marker for determining response to chemotherapy in advanced gastric cancer (AGC)
Authors: S. Matsusaka, K. Chin, N. Mizunuma, M. Ogura, M. Suenaga, E. Shinozaki, Y. Terui, K. Hatake
Journal: Journal of Clinical Oncology (2009)

4600 Background: The purpose of this study was to quantitate circulating tumor cells (CTCs) in advanced gastric cancer (AGC) patients and to demonstrate the role of CTCs in cancer therapy. This study investigates the hypothesis that CTC levels can predict clinical outcomes in patients with AGC. Methods: Eligibility criteria: PS (ECOG) of 0 to 2; histopathology of adenocarcinoma; adequate major organ functions. Chemotherapy regimen was S-1 based regimen (S-1 with or without cisplatin) or paclitaxel. Treatment was continued unless disease progression was observed. CTCs of whole blood in baseline, 2 week and 4 week after initiation of chemotherapy were isolated and enumerated using immunomagnetics. Results: From November 2007 to September 2008, thirty patients with unresectable or recurrent gastric cancer were enrolled onto a prospective study. Pts characteristics were as follows: median age: 60 years (range 24–78), PS 0/1/2: 21/8/1, primary tumor ±: 21/9 and regimen S-1/S-1with cisplatin/paclitaxel: 3/15/12. Among 30 pts, best response rates were 36.7% (CR/PR/SD/PD: 0/11/8/11). Patients with ≥4 CTCs at 2 week points and 4 week points had the shorter median progression-free survival (PFS) (1.4, 1.4 months, respectively), than the median PFS of &lt;4 CTCs (6.3, 6.3 months, respectively) (logrank test; p=0.0008, p=8.78E-07, respectively). A finding of &lt;4, CTCs of 2 week and 4 week after initiation of chemotherapy was associated with significantly longer overall survival (OS) as compared with these patients with ≥4 CTCs (p=0.016702, p=0.027788 respectively). Conclusions: These data demonstrate that CTC measurement may be useful as a surrogate marker for determining response to S1 based regimen or paclitaxel regimen in AGC. No significant financial relationships to disclose.
Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.
Authors: Kathleen N. Moore, Johanna C. Bendell, Anthony J. Olszanski, Madhuri Desai, Mendel Jansen, Richard David Scheyer, Giorgio Senaldi, Patricia LoRusso
Journal: Journal of Clinical Oncology (2013)

2519 Background: Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is an EGF family member and a ligand for EGFR and Her4. U3-1565 is a fully human anti-HB-EGF monoclonal antibody with preclinical anti-tumor and anti-angiogenesis activity. In this study, we evaluated safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of U3-1565 in patients with advanced solid tumors refractory to standard treatment. Methods: The 3+3 method of enrollment and dose-escalation was used to test U3-1565 at 2, 8, 16, and 24 mg/kg once every two weeks (with the second dose given three weeks after the first), and at 24 mg/kg weekly. Results: 15 patients (11 females, 4 males; median age 62 (range 47-77) years; 5 CRC, 5 NSCLC, 3 ovarian and 2 other cancer) were enrolled, 3 in each dose level cohort. No dose-limiting toxicity was observed and a maximum tolerated dose was not reached. The highest administered dose of 24 mg/kg weekly generated Cmin above the predetermined target concentration corresponding to Cave resulting in 90% preclinical tumor growth inhibition. U3-1565 was safe and well tolerated with related AE consisting of infrequent and non-dose-related G2 (fatigue, anemia, and appetite loss, seen in 20, 13, and 7% of cases, respectively) and G1 toxicities. No anti-U3-1565 antibody was detected. U3-1565 showed bi-exponential disposition with Cmax and AUC increasing proportional to the dose across all dosing regimens. 13 patients discontinued the study, 12 due to progressive disease and 1 due to non-drug-related AE. After 6 months on study, 2 patients entered study extension phase: A 77 year-old female with NSCLC given 24 mg/kg every two weeks, showed SD (best SLD change -3%) for 26 weeks before progression; and a 76 year-old female with CRC given 24 mg/kg weekly, showed PR (best SLD change -35%) and remains on treatment after 71 weeks. Conclusions: U3-1565 is safe and well tolerated up to 24 mg/kg weekly. Anti-tumor activity was observed and is being further explored in an open-label, dose-expansion study. Clinical trial information: NCT0129041.
GANGLIONATED PLEXI STIMULATION INDUCES PULMONARY VEIN TRIGGERS AT LEFT ATRIUM-PULMONARY VEIN JUNCTION CHANGING WAVE DYNAMICS: IN SILICO MODELING STUDY
Authors: Minki Hwang, Byounghyun Lim, Jun-Seop Song, Young-Seon Lee, Eun Bo Shim, Hui-Nam Pak
Journal: Journal of the American College of Cardiology (2017)
Chemotherapy-Related Amenorrhea (CRA) among Premenopausal Patients Treated for Acute Leukemia.
Authors: Suzanne R. Fanning, Tao Jin, Joanne M. Hilden, Anjali Advani, Matt Kalaycio, Alan E. Lichtin, Mikkael A. Sekeres, Ronald Sobecks, Halle C.F. Moore
Journal: Blood (2006)